Key Segmentation:
By Test Type
-
Kidney Function Tests
-
Glucose Tests
-
Liver Function Tests
-
Electrolyte Tests
By Disease
-
Kidney Diseases
-
Diabetes
-
Liver Diseases
-
Others
By End User
-
Laboratories
-
Point of Care Centers
-
Others
By Panel Type
-
Basic Panel
-
Expanded Panel
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players in the market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter, Quest Diagnostics, and Labcorp, among others.
Key opportunities include point of care testing platforms that deliver a full panel from a small sample, and decentralized sample collection through capillary draws, home sampling, and mobile phlebotomy.
The rising burden of diabetes, kidney disease, and liver conditions is the major growth factor. These conditions require repeated laboratory monitoring and place the panel in routine checkups and hospital protocols.
The Kidney Function Tests segment dominated the market in 2025 with approximately 31.12% share, as creatinine and urea results guide drug dosing, imaging decisions, and chronic disease staging.
North America dominated the market in 2025 with approximately 37.48% share, supported by high routine testing rates, large reference laboratory networks, and broad insurance coverage.
